RNS Number:5193J
Medical Marketing Int'l Group PLC
02 April 2003


For Immediate Release                                               2 April 2003


                                      MMI

           ANNOUNCES THIRD SUCCESS FOR ITS CANCER BUSINESS, ONCOSENSE

         Important Progress Also Made On Two Other Key Cancer Programmes


Medical Marketing International Group plc the Cambridge, UK-based technology
management company listed on the London Stock Exchange (LSE : MMG) has today
released details of progress with a third anti-cancer technology being developed
by Oncosense, MMI's wholly-owned cancer therapeutics business.

Commenting on this development, Dr Janette Thomas, MMI's Research and
Development Manager, said "We now know that an enzyme we have been developing to
treat serious infections will also remove the protective coating that surrounds
some secondary cancer tumour cells or metastases. There is evidence in the
scientific literature that this coating is implicated in the formation of
metastases. Currently, metastases are difficult to treat, and although this
technology is at a very early stage if we are able to stop or reduce the
formation of metastases, this would be a significant step forward in cancer
therapy".

Further Two Programmes Announce Significant Progress

First Programme

Oncosense has previously announced (20th January 2003) that it is developing a
series of compounds based on the metal ruthenium in collaboration with the
University of Edinburgh. MMI can also confirm today that several of these
compounds have now been shown to kill anti-cancer cells in both in vitro and in
vivo tests, even where some of these cancer cells are known to be resistant to
other drugs.

Second Programme

Additionally, MMI can also confirm that it now has three versions of its
pineapple extract, all of which have been independently verified to kill human
cancer cells in in vitro tests. Significantly one version has already
demonstrated its effectiveness within an in vivo test and the remaining versions
are scheduled to begin in vivo testing this month.

Cancer has now overtaken heart disease as the biggest cause of premature death
in both the USA and Scotland. The global market for cancer therapeutics is
currently worth #15 billion and is expected to reach #20 billion by 2005.


Further information from:-

David Best, Executive Chairman
MMI Group                                                          01223 477677
Dr Janette Thomas, Research and Development Manager
MMI Group                                                          01223 477677
Lisa Baderoon
Buchanan Communications                                            0207 466 5000
Neil Baldwin
Brewin Dolphin Securities                                          0113 241 0130



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
RESNKDKKFBKDFQK